Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #18 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 30 Mar 2017 | GlaxoSmithKline Pte Ltd | Promoter | Buy | 0 | ₹0 |
| 30 Mar 2017 | Castleton Investment Ltd | Promoter group | Sell | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 17 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 11,841 | 1378.6500 | BSE |
| 17 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 11,841 | 1378.6500 | BSE |
| 17 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 80,615 | 1378.6500 | BSE |
| 17 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Buy | 80,615 | 1378.6500 | BSE |
| 11 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 11,417 | 1393.4500 | BSE |
| 11 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 11,417 | 1393.4500 | BSE |
| 11 Oct 2022 | ISHARES CORE EMERGING MARKETS MAURITIUS CO | Block | Sell | 77,734 | 1393.4500 | BSE |
| 11 Oct 2022 | ISHARES CORE MSCI EMERGING MARKETS ETF | Block | Buy | 77,734 | 1393.4500 | BSE |
| 3 Oct 2022 | ISHARES MSCI INDIA SMALL-CAP ETF | Block | Buy | 11,373 | 1424.4000 | NSE |
| 3 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 11,373 | 1424.4000 | NSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| 29 May 2026 | Dividend - Rs 57 Per Share | 57.0000 | 29 May 2026 |
| 30 May 2025 | Dividend - Rs 42 Per Share | 42.0000 | 30 May 2025 |
| 7 Nov 2024 | Interim Dividend - Rs 12 Per Share | 12.0000 | 7 Nov 2024 |
| 31 May 2024 | Dividend - Rs 32 Per Share | 32.0000 | 31 May 2024 |
| 30 Jun 2023 | Dividend - Rs 32 Per Share | 32.0000 | 30 Jun 2023 |
| 7 Jul 2022 | Dividend - Rs 30 Per Share/Special Dividend- Rs 60 Per Share | 30.0000 | 8 Jul 2022 |
| 19 Jul 2021 | Annual General Meeting/Dividend - Rs 30 Per Share | 30.0000 | 20 Jul 2021 |
| 17 Jul 2020 | Dividend - Rs 20 And Special Dividend - Rs 20 Per Share | 20.0000 | 20 Jul 2020 |
| 11 Jul 2019 | Annual General Meeting/Dividend Rs 20 Per Share | 20.0000 | — |
| 13 Jul 2018 | Dividend- Rs 35 Per Share | 35.0000 | — |
Bonuses, splits, buybacks and other events. Dividends are listed separately above.
| Ex-date | Type | Subject |
|---|---|---|
| 11 Sep 2018 | BONUS | Bonus 1:1 |
| — | NAME_CHANGE | Name changed from Glaxo (India) Ltd. to GlaxoSmithkline Pharmaceuticals Ltd. |
| 18 Mar 2009 | OTHER | Div Fin-Rs.22 + Spl-Rs.18 |
| 2 Apr 2008 | OTHER | Div Fin-Rs18+Spl-18 Pr Sh |
| 14 Mar 2007 | OTHER | Div Fin-170% + Spl-140% Purpose Revised |
| 24 Mar 2006 | OTHER | Fin Div-Rs14+Spl Div-Rs14 |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 3 Aug 2026 | Financial Results | Yes |
| 13 May 2026 | Financial Results/Dividend | Yes |
| 9 Feb 2026 | Financial Results | Yes |
| 6 Nov 2025 | Financial Results | Yes |
| 1 Aug 2025 | Financial Results | Yes |
Exchange disclosures (NSE and BSE), most recent first.
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Single-stock futures available for this stock -- OI buildup, PCR, Max Pain and Greeks are all on the full F&O page.
Part of: NIFTY 500, NIFTY 500, NIFTY MIDCAP 150, NIFTY MIDCAP 150
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
